CNBC   |  August 25, 2014

What Roche gets from InterMune

Switzerland's Roche is buying InterMune for $8.3 billion. CNBC's Meg Tirrell reports InterMune's Esbriet drug could draw more than $1 billion in annual revenue.

Share This:

Sorry, we do not have a transcript available for this video at this time.